DAB2IP in cancer

Liang Liu, Cong Xu, Jer Tsong Hsieh, Jianping Gong, Daxing Xie

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

DOC-2/DAB2 is a member of the disable gene family that features tumorinhibiting activity. The DOC-2/DAB2 interactive protein, DAB2IP, is a new member of the RasGTPase-activating protein family. It interacts directly with DAB2 and has distinct cellular functions such as modulating different signal cascades associated with cell proliferation, survival, apoptosis and metastasis. Recently, DAB2IP has been found significantly down regulated in multiple types of cancer. The aberrant alteration of DAB2IP in cancer is caused by a variety of mechanisms, including the aberrant promoter methylation, histone deacetylation, and others. Reduced expression of DAB2IP in neoplasm may indicate a poor prognosis of many malignant cancers. Moreover, DAB2IP stands for a promising direction for developing targeted therapies due to its capacity to inhibit tumor cell growth in vitro and in vivo. Here, we summarize the present understanding of the tumor suppressive role of DAB2IP in cancer progression; the mechanisms underlying the dysregulation of DAB2IP; the gene functional mechanism and the prospects of DAB2IP in the future cancer research.

Original languageEnglish (US)
Pages (from-to)3766-3776
Number of pages11
JournalOncotarget
Volume7
Issue number4
DOIs
StatePublished - 2016

Keywords

  • AIP1
  • Cancer
  • DAB2IP
  • Tumor suppressor

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'DAB2IP in cancer'. Together they form a unique fingerprint.

  • Cite this

    Liu, L., Xu, C., Hsieh, J. T., Gong, J., & Xie, D. (2016). DAB2IP in cancer. Oncotarget, 7(4), 3766-3776. https://doi.org/10.18632/oncotarget.6501